About: The Use and Benefit of Adjuvant Radiotherapy in Parathyroid Carcinoma: A National Cancer Database Analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The Use and Benefit of Adjuvant Radiotherapy in Parathyroid Carcinoma: A National Cancer Database Analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The Use and Benefit of Adjuvant Radiotherapy in Parathyroid Carcinoma: A National Cancer Database Analysis
Creator	Bains, Sarina Beninato, Toni Fahey Iii, Thomas Finnerty, Brendan Limberg, Jessica Stefanova, Dessislava Thiesmeyer, Jessica Ullmann, Timothy Zarnegar, Rasa
Source	Medline; PMC
abstract	BACKGROUND: The routine use of external beam radiotherapy (EBRT) is not recommended for parathyroid carcinoma (PC). However, case series have demonstrated a potential benefit in preventing local recurrence with EBRT. We aimed to characterize the patient population treated with EBRT and identify any impact of EBRT on overall survival (OS) in parathyroid carcinoma. METHODS: Patients who underwent surgery for PC from 2004 to 2016 were identified from the National Cancer Database. Clinicopathologic variables and OS were compared between patients based on treatment with EBRT. Multivariable logistic and Cox regression models were performed with propensity scores and inverse-probability-weighting (IPW) adjustment to reduce treatment-selection bias in the OS analysis. RESULTS: A total of 885 patients met the inclusion criteria, with 126 (14.2%) undergoing EBRT. Demographics were similar between the two cohorts (EBRT vs. no EBRT). However, patients treated with EBRT had a higher frequency of regionally extensive disease, nodal metastases, and residual microscopic disease (all p < 0.05). On multivariable analysis, Black race, regional tumor extension, nodal metastasis, and treatment at an urban facility were independently associated with EBRT. The 5-year OS was 85.3% with a median follow-up of 60.8 months. EBRT was not associated with a difference in OS in crude, multivariable, or IPW models. More importantly, 10.5% of patients with completely resected localized disease (M0, N0 or Nx) underwent EBRT without a benefit in OS (p = 0.183). CONCLUSIONS: EBRT is not associated with any survival benefit in the treatment of PC. Therefore, it may be overutilized, particularly in patients with localized disease and complete surgical resection.
has issue date	2020-07-13(xsd:dateTime)
bibo:doi	10.1245/s10434-020-08825-8
bibo:pmid	32661850
has license	no-cc
sha1sum (hex)	2d10b07f5aeba43270acfb7503e53aa8df39b564
schema:url	https://doi.org/10.1245/s10434-020-08825-8
resource representing a document's title	The Use and Benefit of Adjuvant Radiotherapy in Parathyroid Carcinoma: A National Cancer Database Analysis
has PubMed Central identifier	PMC7357448
has PubMed identifier	32661850
schema:publication	Ann Surg Oncol
resource representing a document's body	covid:2d10b07f5aeba43270acfb7503e53aa8df39b564#body_text
is schema:about of	named entity 'However' named entity 'identify' named entity 'EBRT' named entity 'population' named entity 'treated' named entity 'microscopic' named entity 'nodal' named entity 'EBRT' named entity 'Results' named entity 'National' named entity 'BENEFIT' named entity 'OVERALL SURVIVAL' named entity 'POTENTIAL' named entity 'YEAR' named entity 'FOLLOW-UP' named entity 'SIMILAR' named entity 'URBAN' covid:arg/2d10b07f5aeba43270acfb7503e53aa8df39b564 named entity 'race' named entity 'EBRT' named entity 'identified' named entity 'extension' named entity 'IPW' named entity 'surgery' named entity 'residual' named entity 'demonstrated' named entity 'external beam radiotherapy' named entity 'Cox regression models' named entity 'metastasis' named entity 'EBRT' named entity 'median follow-up' named entity 'EBRT' named entity 'IPW' named entity 'met' named entity 'intraoperative' named entity 'EBRT' named entity 'refractory disease' named entity 'case series' named entity 'radioresistant' named entity 'adjuvant' named entity 'adjuvant' named entity 'parathyroidectomy' named entity 'oncologic' named entity 'adjuvant' named entity 'Descriptive statistics' named entity 'tumor' named entity 'metastasis' named entity 'metastasis' named entity 'case series' named entity 'resections' named entity 'case series' named entity 'EBRT' named entity 'resections' named entity 'EBRT' named entity 'EBRT' named entity 'metastasis' named entity 'parathyroidectomy' named entity 'EBRT' named entity 'resection margin' named entity 'hypercalcemia' named entity 'surgical resection' named entity 'rare disease' named entity 'EBRT' named entity 'Adjuvant' named entity 'EBRT' named entity 'Median household income' named entity 'external beam radiotherapy' named entity 'benign neoplasms' named entity 'hemithyroidectomy' named entity 'zip code' named entity 'older age' named entity 'logistic regression' named entity 'Tumor'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software